Recent National and Regional Drug Reforms in Sweden

[1]  A. Oxman,et al.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2014, The Cochrane database of systematic reviews.

[2]  S. Garattini,et al.  Non-inferiority trials are unethical because they disregard patients' interests , 2007, The Lancet.

[3]  S. Garattini,et al.  How can we regulate medicines better? , 2007, BMJ : British Medical Journal.

[4]  A D Oxman,et al.  Educational outreach visits: effects on professional practice and health care outcomes. , 2007, The Cochrane database of systematic reviews.

[5]  M. Niezen,et al.  The Increasingly Complex Fourth Hurdle for Pharmaceuticals , 2007, PharmacoEconomics.

[6]  D. Larsson,et al.  Effluent from drug manufactures contains extremely high levels of pharmaceuticals. , 2007, Journal of hazardous materials.

[7]  Richard Hoey.  Experts disagree over NICE's approach for assessing drugs , 2007, The Lancet.

[8]  Jane Wells,et al.  NICE appraisals should be everybody's business , 2007, BMJ : British Medical Journal.

[9]  I. Karlberg,et al.  Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. , 2007, Health policy.

[10]  J. Catineau,et al.  Endpoints in studies on myocardial infarction , 2007, The Lancet.

[11]  M. Petzold,et al.  Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. , 2006, Health policy.

[12]  Bengt Jönsson,et al.  The costs and benefits of regulations for reimbursement of new drugs. , 2006, Health policy.

[13]  Ann Barrett,et al.  How much will Herceptin really cost? , 2006, BMJ : British Medical Journal.

[14]  B. Wettermark,et al.  [Quality indicators for drug prescribing--the situation in Sweden]. , 2006, Lakartidningen.

[15]  S. Jansson,et al.  The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness. , 2006, Health policy.

[16]  C. Furberg,et al.  Pharmaceutical policies: effects on rational drug use , 2006 .

[17]  Peter Forsberg,et al.  Janus computerised prescribing system provides pharmacological knowledge at point of care – design, development and proof of concept , 2006, European Journal of Clinical Pharmacology.

[18]  Magnus Wikström,et al.  Fixed budgets as a cost containment measure for pharmaceuticals , 2006, The European Journal of Health Economics.

[19]  A. Anell,et al.  Reimbursement and clinical guidance for pharmaceuticals in Sweden , 2005, The European Journal of Health Economics.

[20]  Anders Anell,et al.  Swedish healthcare under pressure. , 2005, Health economics.

[21]  G. Apolone,et al.  Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures , 2005, British Journal of Cancer.

[22]  B. Wettermark,et al.  A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists , 2005, Pharmacoepidemiology and drug safety.

[23]  M. Petzold,et al.  What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden , 2005, Pharmacoepidemiology and drug safety.

[24]  B. Wettermark.  Drug utilization 90 % : Using aggregate drug statistics for the quality assessment of prescribing , 2004 .

[25]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[26]  Peter C Smith,et al.  Quality incentives: the case of U.K. general practitioners. , 2004, Health affairs.

[27]  F. Rocchi,et al.  Current National Initiatives About Drug Policies and Cost Control in Europe: The Italy Example , 2004, The Journal of ambulatory care management.

[28]  U. Gerdtham,et al.  Why did drug spending increase during the 1990s? , 2004, PharmacoEconomics.

[29]  B. Wettermark,et al.  Drug utilisation 90% profiles—a useful tool for quality assessment of prescribing in primary health care in Stockholm , 2003, Pharmacoepidemiology and drug safety.

[30]  C. Pen.  The Drug Budget Silo Mentality: The French Case , 2003 .

[31]  A. Haycox,et al.  Having Your Cake and Eating It , 2012, PharmacoEconomics.

[32]  R. Carbajal,et al.  Endpoints in studies on myocardial infarction , 2007 .

[33]  A. Oxman,et al.  Pharmaceutical policies: effects of financial incentives for prescribers. , 2007, The Cochrane database of systematic reviews.

[34]  A D Oxman,et al.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2006, The Cochrane database of systematic reviews.

[35]  K. Hassell,et al.  Affordability of medicines and patients’ cost-reducing behaviour , 2005, Applied health economics and health policy.

[36]  M. Drummond,et al.  Reimbursement of pharmaceuticals in the European Union , 2004 .

[37]  U. Bergman,et al.  Five years' experience of quality assurance and feedback with individual prescribing profiles at a primary healthcare centre in Stockholm, Sweden , 2004 .

[38]  C. Le Pen.  The drug budget silo mentality: the French case. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  U Bergman,et al.  Drug and Therapeutics committees:a Swedish experience. , 2002 .

[40]  M. Drummond,et al.  Influencing Prescribing in a Primary Care Led NHS , 2002 .

[41]  J. Lundkvist.  Pricing and reimbursement of drugs in Sweden , 2001, The European Journal of Health Economics.

[42]  L. Gustafsson,et al.  “Academic drug-detailing”: from project to practice in a Swedish urban area , 1997, European Journal of Clinical Pharmacology.